The Core normally provides diagnosis and care to a large number of patients with Alzheimer's disease (AD), and can provide a pool of thoroughly evaluated AD patients and controls for clinical investigation and autopsy studies. These subjects will be utilized in this Program Project for studies of peripheral endocrine and calcium regulation and a therapeutic trial in Project 5, and autopsy tissue will be utilized in Projects 1 and 2 of the program project proposal. Periodic reassessment of the cognitive capabilities of the patients, their level of independent functioning, and the relative rates of their functional decline offer a seminal opportunity for correlative clinical-pathological-neurochemical studies. All quantitative data on patients will be kept in a computer designed for storage, search and retrieval of clinical information. In addition, patients in the mild to moderate stage of """"""""probable"""""""" AD will be recruited for the Calcitriol (1,25(OH)2D) study in Project 5. These patients will have a gradually progressive intellectual decline, have a Mini-Mental State Exam score between 24 and 12, a mild to moderate rating on the Alzheimer's Disease Assessment Scale and the Dementia Rating Scale and a Clinical Dementia Rating of 1 or 2 (moderate). Other criteria for inclusion in the Calcitriol study are outlined in Project 5 of the program project proposal.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010836-05
Application #
5204854
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Chen, Chun-Hau; Li, Wenzong; Sultana, Rukhsana et al. (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis 76:13-23
Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95
Barone, Eugenio; Di Domenico, Fabio; Mancuso, Cesare et al. (2014) The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis 62:144-59
Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9
Swomley, Aaron M; Förster, Sarah; Keeney, Jierel T et al. (2014) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 1842:1248-57
Latimer, Caitlin S; Brewer, Lawrence D; Searcy, James L et al. (2014) Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A 111:E4359-66
Butterfield, D Allan; Di Domenico, Fabio; Barone, Eugenio (2014) Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 1842:1693-706
Perluigi, Marzia; Di Domenico, Fabio; Buttterfield, D Allan (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl 8:73-85
Farr, Susan A; Ripley, Jessica L; Sultana, Rukhsana et al. (2014) Antisense oligonucleotide against GSK-3? in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67:387-95

Showing the most recent 10 out of 356 publications